Cerebrolysin

Typical use cases

Dosing guidelines

Titration

In trials, doses are typically fixed per protocol and delivered as defined treatment courses (e.g., daily for 10-20 days) rather than gradually titrated; larger volumes are given by slow IV infusion in clinical settings. Community use is commonly described as cyclical courses rather than continuous dosing.

Reconstitution

N/A — supplied as a sterile aqueous solution in ampoules/vials; not a lyophilized powder requiring reconstitution. Smaller volumes are given IM undiluted; larger volumes are diluted in a compatible IV solution for slow infusion per the product labeling.

Injection sites

Intramuscular (volumes up to ~5 mL) or intravenous; larger doses given by slow IV infusion. IM sites are typically large muscles such as the gluteal or thigh.

Storage & handling

Store the aqueous solution per manufacturer labeling, typically below 25 C, protected from light; do not freeze. Use promptly once an ampoule is opened.

Side effects

• Headache Mild · Common
• Dizziness Mild · Common
• Nausea Mild · Uncommon
• Sweating or flushing Mild · Uncommon
• Injection-site reaction or irritability after injection Mild · Uncommon
• Seizure aggravation in susceptible individuals (e.g., epilepsy) Severe · Rare

Research summary

Cerebrolysin is produced by controlled enzymatic proteolysis of lipid-free porcine brain proteins, yielding a standardized mixture that is roughly three-quarters free amino acids and one-quarter biologically active peptides (under ~10 kDa); the peptide fraction is considered the active component and is reported to mimic endogenous neurotrophic factors such as BDNF, NGF, GDNF, and CNTF, with preclinical work implicating TrkB/TrkA receptor activation and PI3K/Akt/GSK-3 signaling. The human evidence base is sizeable but mixed. A 2021 systematic review/meta-analysis of 12 randomized double-blind placebo-controlled trials (2,202 patients) in acute ischemic stroke reported a safety profile broadly comparable to placebo, with no statistically significant differences in mortality or overall serious adverse events. However, a 2023 Cochrane review of acute ischaemic stroke concluded Cerebrolysin probably has no beneficial effect on all-cause death and flagged a potential increase in non-fatal serious adverse events, and did not support routine use. Efficacy signals are modest and inconsistent: some stroke meta-analyses found no clear benefit on long-term functional outcomes (modified Rankin Scale, Barthel Index). In mild-to-moderate Alzheimer's disease, a meta-analysis of randomized trials suggested benefits on global clinical impression and cognition, but methodological limitations temper confidence. Small trials in other settings (e.g., perinatal brain injury in infants, traumatic brain injury) have reported encouraging but preliminary results. Major limitations include heterogeneity of trial design, batch-to-batch compositional variability inherent to a tissue-derived mixture, and that the product is not approved in the United States (it is marketed in Russia, Eastern Europe, China, and parts of Asia by Ever Pharma).

Key references

• https://en.wikipedia.org/wiki/Cerebrolysin
• https://pmc.ncbi.nlm.nih.gov/articles/PMC8708612/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4712290/
• https://pmc.ncbi.nlm.nih.gov/articles/PMC10565895/
• https://pubmed.ncbi.nlm.nih.gov/25832905/
• https://pubmed.ncbi.nlm.nih.gov/28656143/

Related compounds